Secondary outcomes
In analyses evaluating the relationship of baseline LVMi and change in LVESVi from baseline to 6 months, we observed no significant association (
Association between treatment with empagliflozin (10 mg/d) and 6-month changes in LVESVi, LVEDVi, and LVEF stratified by baseline LVMi of ≤ 60 g/mLVEDVi; left ventricular end diastolic volume indexed; LVESVi, left ventricular end systolic volume indexed; LVEF, left ventricular ejection fraction.